Table 6. Randomized trial of non-vitamin K oral anticoagulants for patients with cancer associated thrombosis^152,154-156.

	Hokusai VTE Cancer	SELECT-D	ADAM VTE	Caravaggio
	NCT02073682	ISRCTN86712308	NCT02585713	NCT03045406
Publication year	2018	2018	2020	2020
Patient no.	1050	406	300	1170
Study arm treatment	Edoxaban 60 mg (30 mg in patients with CrCl of 30 to 50 mL/min or weight of 60 kg or less or in those receiving concomitant treatment with potent P-glycoprotein inhibitors) once daily after 5-day low-molecular-weight heparin lead-in	Rivaroxaban, 15 mg twice daily for the first 3 weeks followed by 20 mg once daily	Apixaban 10 mg twice daily for 7 days followed by 5 mg twice daily	Apixaban 10 mg twice daily for 7 days followed by 5 mg twice daily
Control arm treatment	Dalteparin 200 IU/kg once daily for 30 days then 150 IU/kg once daily	Dalteparin 200 IU/kg once daily for 30 days then 150 IU/kg once daily	Dalteparin 200 IU/kg once daily for the first month followed by 150 IU/kg	Dalteparin 200 IU/kg once daily for the first month followed by 150 IU/kg
Study duration	12 months	6 months	6 months	6 months
Specific exclusion	ECOG performance status > 2	Weight < 40 kg	CrCl < 30 mL/min	ECOG performance status > 2
	CrCl < 30 mL/min	ECOG performance status > 2	Concomitant use of strong CYP3A4 inducers	CrCl < 30 mL/min
	Concomitant use of P-glycoprotein inhibitors	Concomitant use of strong CYP3A4 inhibitors or inducers or P-glycoprotein inhibitors or inducers		Concomitant use of strong CYP3A4 inhibitors or inducers or P-glycoprotein inhibitors or inducers
	Thrombocytopenia (< 50000/μL)	Primary esophageal or gastro-esophageal cancer		Thrombocytopenia (< 75000/μL)
Primary endpoint	Recurrent VTE or major bleeding	Recurrent VTE	Major bleeding	Recurrent VTE

CrCl, creatinine clearance; CYP, cytochrome P-450; ECOG, Eastern Cooperative Oncology Group; VTE, venous thromboembolism.